UCL researchers develop an AI tool to predict brain tumor MRI enhancement, reducing the need for gadolinium contrast agents.
Key Details
- 1AI tool designed to predict which brain tumor areas would enhance with contrast on MRI.
- 2Developed by a team at University College London (UCL).
- 3Tool aims to minimize unnecessary exposure to gadolinium-based contrast agents (GBCAs).
- 4GBCAs can accumulate in the body and are a concern for patients with kidney disease, allergies, or those needing frequent follow-ups.
- 5Model validated to work from non-contrast MRI sequences alone.
Why It Matters
Reducing routine use of GBCAs may lower patient risk, especially among those with renal impairment or allergies, while still enabling accurate tumor monitoring. AI-driven solutions like this offer a path toward safer and more efficient MR imaging protocols in oncology.
Source
Radiology Business
Related News
•Radiology Business
UC Irvine Implements AI to Find Lung Cancer Screening Candidates
UC Irvine's radiology department developed an NLP tool to identify patients eligible for lung cancer screening from EHR notes.
•Radiology Business
Webinar to Showcase Successful AI Automation in Radiology Workflows
A webinar will provide insights from imaging leaders on expanding and optimizing AI-driven automation in radiology clinical workflows.
•Radiology Business
A Practical Guide to Evaluating Radiology AI Solutions
Experts propose a three-step approach for radiologists to assess and select AI imaging solutions.